Hatice ŞAHİN
Eurasian Journal of Toxicology - 2025;7(3):43-44
This letter discusses the study by Adikwu et al. published in the Eurasian Journal of Toxicology, which demonstrated the hepatoprotective effects of glutamine against antituberculosis drug-induced liver injury (RIPE). While the restoration of liver enzymes and histological improvement with glutamine supplementation is promising, we highlight three critical limitations from a clinical perspective. First is the risk that glutamine might support the growth of Mycobacterium tuberculosis due to the bacterium's nitrogen metabolism. Second is the potential for pharmacokinetic interactions between glutamine and the RIPE regimen that could compromise drug efficacy. Third is the challenge of translating high preclinical doses to often malnourished tuberculosis patients safely. We conclude that further studies using infected models are essential before considering glutamine for clinical application.
